Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen

•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of antimicrobial agents 2023-05, Vol.61 (5), p.106771-106771, Article 106771
Hauptverfasser: Scutari, Rossana, Galli, Laura, Alteri, Claudia, Poli, Andrea, Piermatteo, Lorenzo, Bigoloni, Alba, Perno, Carlo Federico, Lazzarin, Adriano, Ceccherini-Silberstein, Francesca, Castagna, Antonella, Santoro, Maria Mercedes, Gianotti, Nicola
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•HIV-DNA changes over 96 weeks were similar for DTG + 1 RTI and E/C/F/TAF.•Plasma HIV-RNA changes over 96 weeks were similar in the two treatment arms.•A positive correlation was found between baseline HIV-DNA and HIV-DNA levels at W96.•No correlations were found between HIV-DNA and immunological parameters over time.•No correlations were generally found between viremia and immunological parameters. To investigate HIV-DNA and residual viremia (RV) levels over 96 weeks (W96) in virologically-suppressed HIV-1-infected individuals enrolled in the Be-OnE Study. Individuals were randomised to continue a two-drug regimen with dolutegravir (DTG) plus one reverse transcriptase inhibitor (RTI) or to switch to elvitegravir/cobicistat/emtricitabine/tenofovir-alafenamide (E/C/F/TAF). Total HIV-DNA and RV were evaluated at baseline, W48 and W96 using droplet digital polymerase chain reaction (ddPCR) technique. Potential relationships between viro-immunological parameters and between/within arms were also assessed. Median (interquartile range [IQR]) HIV-DNA was 2247 (767-4268), 1587 (556-3543) and 1076 (512-2345) copies/106 CD4+T-cells at baseline, W48 and at W96, respectively; RV was 3 (1-5), 4 (1-9) and 2 (2-4) copies/mL, respectively, with no significant differences between arms. A significant reduction in HIV-DNA and RV from baseline to W96 was observed in the E/C/F/TAF arm (HIV-DNA: -285 [-2257; -45], P=0.010; RV: -1 [-3;0], P=0.007). In the DTG + 1 RTI arm, HIV-DNA and RV levels remained stable (HIV-DNA: -549 [-2269;+307], P=0.182; RV: -1 [-3;+1], P=0.280). For both HIV-DNA and RV, there were no significant changes over time between the arms. A positive correlation was found between baseline HIV-DNA and HIV-DNA at W96 (E/C/F/TAF: Spearman correlation coefficient (rs)=0.726, P=0.0004; DTG + 1 RTI: rs=0.589, P=0.010). In general, no significant correlations were found between HIV-DNA, RV and immunological parameters over time. In virologically-suppressed individuals, there was a small reduction in HIV-DNA and HIV-RNA levels from baseline to W96 in individuals who switched to the E/C/F/TAF arm compared with those who remained on DTG + 1 RTI. However, there were no significant differences between the two arms in the changes in HIV-DNA and HIV-RNA over time.
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2023.106771